Long-term effects on bone mineral density and bone metabolism of 6 months’ treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate
article
OA: closed
CC0
⤵ 6 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (30)
- A Comparison of the Skeletal Effects of Goserelin and Danazol in Premenopausal Women with Endometriosis via openalex
- Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. via openalex
- Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis via openalex
- Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results via openalex
- Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis via openalex
- Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered via openalex
- Gonadotropin releasing hormone agonist therapy and its effect on bone mass via openalex
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? via openalex
- Nafarelin therapy in endometriosis: Long-term effects on bone mineral density via openalex
- New Therapy for Endometriosis via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. via openalex
- REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMEN via openalex
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment via openalex
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. via openalex
- Treatment of Endometriosis via openalex
- Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group. via openalex
- W2153895111 via openalex
- W2059516397 via openalex
- W2049987798 via openalex
- W2031495520 via openalex
- W2322133447 via openalex
- W2337521034 via openalex
- W2394707818 via openalex
- W2409164901 via openalex
- W2414394097 via openalex
- W2416265216 via openalex
- W2123876576 via openalex
- W2014486464 via openalex
- W2129449855 via openalex
- W2009881284 via openalex
Cited by (6)
- The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis 2022
- A patient developing anaphylaxis and sensitivity to two different GnRH analogues and a review of literature 2015
- The effect of macrophages on fibroblast activity and lesion development in mouse models of endometriosis. 2014
- The immninent dawn of SPRMs in obstetrics and gynecology 2012
- [Endometriosis: necessary and sequential therapeutic procedures and guidelines]. 2011
- Endometriosis: Necessary and Sequential Therapeutic Procedures and Guidelines 2010
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:15:35.797702+00:00
License: CC0
· commercial use OK